Verisante Technology, Inc. Retains Crescendo Communications for Investor Relations
VANCOUVER, BRITISH COLUMBIA, Jan 29, 2013 (Marketwire via COMTEX) --
Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, today announced that it has retained Crescendo Communications, LLC ("Crescendo") to help increase investor awareness throughout North America.
"We are pleased and excited to start working with Verisante, whose breakthrough skin cancer detection device has the potential to save millions of lives through early detection. Not only has the Aura(TM) been recently approved for sale in Canada, Europe and Australia, but U.S. approval is now underway. Moreover, the technology is applicable to lung, gastro-intestinal, colorectal, cervical and other cancers, which represent sizable yet untapped markets. For this reason, we believe it is a great time to begin increasing awareness of Verisante in advance of a number of important financial and other milestones we expect this year. We believe the significant potential of their proprietary technology, coupled with a well-crafted commercialization strategy, will resonate well within the investment community," commented David Waldman, President & CEO of Crescendo.
"The team at Crescendo has extensive experience within the healthcare market and a successful track record working with small-cap public companies throughout North America," said Thomas Braun, President & CEO of Verisante. "We are confident that Crescendo will help us proactively communicate our business model and upcoming milestones as we move into the next stage of our development."
The agreement with Crescendo is for a period of 12 months. Under the terms of the agreement, the Company will pay a consulting fee to Crescendo of $6,000 per month plus approved expenses incurred on behalf of the Company.
About Crescendo Communications, LLC
Crescendo Communications, LLC, headquartered in New York City with offices in Beijing, Shanghai and Moscow, is an emerging leader within the investor relations industry. The firm was founded on a strategic and professional approach to investor relations that builds awareness of public companies through tailored outreach programs that target institutional investors, analysts, and the financial media. The firm's approach is centered around properly educating investors and cultivating trust in order to uphold and protect their clients' long-term credibility and reputation on Wall Street and within the global capital markets.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura(TM) for skin cancer detection and the Verisante Core(TM) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura(TM) has been approved for sale in Canada, Europe and Australia. The Core(TM) has not yet been approved for sale.
Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and Verisante Core(TM) was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
FOR FURTHER INFORMATION PLEASE CONTACT:
Verisante Technology, Inc.
President & CEO
Crescendo Communications, LLC David Waldman/Natalya Rudman Investor Relations (212) 671-1020 x304 VRS@crescendo-ir.com www.crescendo-ir.com
SOURCE: Verisante Technology, Inc.
[ Back To TMCnet.com's Homepage ]